Age-associated disorders, including cognitive functions, that often occur in geriatric patients, necessitate the use of novel approaches to provide appropriate medical care, pharmacoprophylaxis and pharmacotherapy among them. At the same time, an important objective of the national healthcare system is not only stimulating of pharmaceutical companies and pharmacies to expand the range of medicines intended for elderly patients, but also increasing availability of medicinal products, including the integration of extemporaneous formulations into clinical practice. Presented review considers several features of the regulation of the use of extemporaneous formulations in the treatment of geriatric patients. Examples of prescriptions that are used in Russian medical practice and are of the greatest interest in the treatment of elderly patients are also presented.
Introduction Dental diseases are among the most prevalent and costly diseases affecting industrialized societies, and yet are highly preventable. For example, in the UK, the National Health Service spends over £1,6 billion per annum on dental treatment, and this figure increases to £2,6 billion if the burgeoning private sector costs are included [1, 2].
The worlds older population is growing dramatically. At the same time, ensuring an appropriate high standard of living for the elderly by reducing of morbidity and disability of geriatric patients is one of the main objectives of the modern healthcare system. However, changes associated with body aging necessitate application of novel approaches to the correction of pharmacotherapy and usage of specialized dosage forms. Such medicinal products provide both an appropriate therapeutic effect and facilitate their use. Presented review considers several features of pharmacotherapy of geriatric patients.
Bacteriophages are promising antibacterial agents for managing acne vulgaris caused by Cutibacterium acnes, particularly given increasing antibiotic resistance. Here, we isolated and characterized two lytic Cutibacterium phages, NS-ph1 and NS-ph2, from acne lesions. Both bacteriophages exhibited a broad lytic spectrum, with a high activity against 27 C. acnes strains. Adsorption assays indicated rapid attachment and one-step growth experiments revealed latent periods of 4 h (NS-ph1) and 2 h (NS-ph2) and burst sizes of 70 and 59 PFU per infected cell, respectively. After long-term storage at room temperature, both phages retained infectivity for 3 months. Genome sequencing revealed linear dsDNA genomes of 29,490 bp (NS-ph1) and 29,189 bp (NS-ph2) with 51 and 46 predicted ORFs, respectively, and no tRNAs. No genes associated with lysogeny, toxins, or antibiotic resistance were detected. Comparative genomics placed both phages within the genus Pahexavirus. Together, these data expand the diversity of Pahexavirus and provide two well-characterized lytic candidates for further evaluation in anti-acne phage therapy.